On Wednesday, Alere Inc (NYSE:ALR)’s shares inclined 3.01% to $52.41.
Alere Inc (ALR) has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock (NYSE:ALR.PR.B). The dividend is payable on July 15, 2015 to holders of record of Series B stock at the close of business on July 1, 2015.
Alere Inc. provides point-of-care diagnostics and services for infectious and cardiometabolic diseases, and toxicology and in the United States and internationally. It operates in three segments: Professional Diagnostics, Patient Self-Testing, and Consumer Diagnostics.
VWR Corp (NASDAQ:VWR)’s shares gained 2.45% to $27.20.
VWR Corp (VWR) declared the pricing of an underwritten public offering of 16,000,000 shares of its common stock by selling stockholder Varietal Distribution Holdings, LLC at a price to the public of $26.25 per share. In connection with the offering, the selling stockholder has granted the underwriters a 30-day option to purchase up to 2,400,000 additional shares. The offering is predictable to close on June 9, 2015. VWR will not receive any proceeds from this offering.
VWR Corporation provides laboratory products, services, and solutions to the life science, general research, and applied markets worldwide. The company operates through two segments, Americas and EMEA-APAC. It offers chemicals, reagents, consumables, durable products, scientific equipment and instruments.
At the end of Wednesday’s trade, Informatica Corporation (NASDAQ:INFA)‘s traded showed no change to $48.47.
Informatica Corporation (INFA) declared that it is sponsoring, presenting and exhibiting at the 2015 Hadoop Summit NorthAmerica - the leading conference for the Apache Hadoopcommunity - planned for June 9-11, at the San Jose ConventionCenter in San Jose, Calif.
Exhibiting at booth P11, Informatica will showcase its big data administration, big data governance, big data mastering and big data security capabilities for delivering more timely and trusted dataon Hadoop. Using Informatica, organizations can quickly adoptHadoop while making it easy for developers to operationalize Hadoopprojects. Attendees can learn how customers are using Informatica solutions to become big data ready and succeed with critical enterprise business initiatives, such as data warehouse optimization, customer engagement, security analytics, risk administration and predictive maintenance.
Informatica Corporation provides enterprise data integration software and services worldwide. Its enterprise data integration products comprise PowerCenter, Power Exchange, and Data Integration Hub, in addition to Power Center Express, an entry-level data integration and profiling edition for departments or small to mid-market business, and cloud data integration solutions.
AstraZeneca plc (ADR) (NYSE:AZN), ended its Wednesday’s trading session with 0.91% gain, and closed at $67.61.
AstraZeneca (AZN) and MedImmune, the Company’s global biologics research and development arm, offered an update on the progress of their combination-focused immuno-oncology pipeline at an investor science event at the American Society of Clinical Oncology (ASCO) meeting in Chicago on June 1, 2015.
Commenting on the Company’s immuno-oncology combination data presented at ASCO, Chief Executive Officer, Pascal Soriot, said: “Immuno-oncology has continued to take center stage at ASCO this year, as we see more evidence of the significance of this approach for patients. At AstraZeneca we have been clear in our belief that combinations hold the key to transforming clinical practice for the patients not benefiting from the presently-accessible immunotherapies. The data presented on the combination of MEDI4736 and tremelimumab are truly exciting. As the frontrunner combination of two immuno-oncology molecules in non-small cell lung cancer, it is demonstrating promising clinical activity, in particular in the majority of patients who have low or no PD-L1 expression. With our longstanding expertise in developing small molecule medicines, counting olaparib and AZD9291, we are now also seeing the potential of combining these targeted medicines with immuno-oncology molecules to deliver efficacious and durable treatment to patients.”
Highlights of the update were:
- Data presented on MEDI4736, the Company’s anti-PD-L1 monoclonal antibody, as monotherapy in heavily pre-treated patients with non-small cell lung cancer (NSCLC) are encouraging and suggest that patients with PD-L1 positive tumors may have an improved overall response rate contrast to patients with PD-L1 negative tumors, highlighting the unmet medical need for the majority of tumors that are PD-L1 negative.
- MEDI4736 is demonstrating strong potential to combine with both immunotherapy and small molecules; AstraZeneca and MedImmune have an extensive development program underway across multiple tumor types and stages of disease, assessing the potential for immunotherapy to either replace or combine with traditional chemotherapy.
Immuno-oncology combinations
- The combination of MEDI4736 and tremelimumab (anti-CTLA-4 monoclonal antibody) is demonstrating efficacy regardless of PD-L1 status, showing promise for the noteworthynumber of patients who fail to respond to anti-PD-1/PD-L1 monotherapy because of their PD-L1 biomarker negative status.
- The combination of MEDI4736 and tremelimumab is also showing a manageable safety profile, with a discontinuation rate due to related adverse events of only 7%.
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
